News

Featured news

Lumos and BARDA to Partner to Support FebriDx® CLIA Waiver Study and Application
3 October 2024

Lumos has been awarded US$2,984,571 from the Biomedical Advanced Research and Development Authority (BARDA)...

Lumos Awarded National Contract with MediGroup for FebriDx®
25 September 2024

Lumos Diagnostics has been awarded placement of their novel POC test, FebriDx®...

Lumos Appoints Thermo Fisher Scientific as US Distributor for FebriDx®
16 September 2024

Lumos Diagnostics has signed an agreement with Fisher Healthcare, a part of Thermo Fisher Scientific...

All news
Lumos Successfully Completes Retail Entitlement Offer
8 October 2024

Lumos Diagnostics has announced that it has successfully completed the retail component of its Entitlement Offer...
Lumos and BARDA to Partner to Support FebriDx® CLIA Waiver Study and Application
3 October 2024

Lumos has been awarded US$2,984,571 from the Biomedical Advanced Research and Development Authority (BARDA)...
Lumos Awarded National Contract with MediGroup for FebriDx®
25 September 2024

Lumos Diagnostics has been awarded placement of their novel POC test, FebriDx®...
Lumos Appoints Thermo Fisher Scientific as US Distributor for FebriDx®
16 September 2024

Lumos Diagnostics has signed an agreement with Fisher Healthcare, a part of Thermo Fisher Scientific...
Lumos Successfully Completes Institutional Component of Entitlement Offer
6 September 2024

Lumos Diagnostics has today announced that it has successfully completed the institutional component...
FY24 Annual Report
27 August 2024

Lumos has today published its Annual Report for FY24...
Video | Q4 FY24 Investor webinar
1 August 2024

Lumos CEO, Doug Ward, Chief Financial Officer, Barrie Lambert, and Senior VP Commercial Operations, Paul Kase...
Lumos Diagnostics Quarterly Activity Statement and Cash Flow Report period ended 30 June 2024
31 July 2024

Lumos Diagnostics has released its Quarterly Report & 4C for the period ending 30 June 2024.
Stockhead | Air supply: The ASX medtechs tackling respiratory illnesses
15 July 2024

Lumos Diagnostics has been included in a Stockhead article spotlighting medtech companies addressing respiratory illness...
Video | Q&A with Paul Kase, SVP, Commercial Operations
12 July 2024

In this Q&A with Paul Kase, Lumos’ SVP, Commercial Operations, Paul outlines how Lumos is working in partnership with Henry Schein...
FebriDx® now available to health care practitioners in Belgium
9 July 2024

Lumos Diagnostics has extended its agreement with Henry Schein Europe, which will see the expansion of distribution of FebriDx® into Belgium...
Lumos Diagnostics Expands Distribution Partnership with Regional Health Care Group, Henry Schein’s Medical Business in Australia and New Zealand, for FebriDx®
4 July 2024

FebriDx® - Lumos’ rapid point-of-care test – is now available to health care practitioners in Australia and New Zealand...
Lumos Receives US$400K Phase 1 Milestone Payment from Hologic
19 June 2024

Lumos Diagnostics announced this week that it has received US$400,000 payment from Hologic...
New FebriDx® Study | Journal of Antimicrobial Chemotherapy
16 May 2024

Antimicrobial resistance (AMR) is a growing threat to global health, driven largely by the overuse of antibiotics...
Lumos Signs Major Development and IP Agreements with Hologic
6 May 2024

Lumos Diagnostics has announced that it has successfully completed the first phase of its Development Agreement...
Quarterly | Interview with LDX CEO, Doug Ward
30 April 2024

In this video, Lumos Diagnostics CEO Doug Ward discusses the Company's recent quarterly activity statement and cash flow report...
Hologic enables maiden net free cash flow
29 April 2024

A wrap-up of Lumos’ performance this Quarter was covered by Foster Stockbroking on ListCorp today...
Lumos to exhibit at 2024 Urgent Care Convention
11 April 2024

Lumos is excited to be exhibiting at the 2024 Urgent Care Convention April 13-17...
New FebriDx® study published in peer-reviewed journal: Infectious Diseases and Clinical Microbiology
8 April 2024

Lumos is pleased to announce that respected international journal, Infectious Diseases...
Lumos Appoints Henry Schein as US Distributor for FebriDx®
12 February 2024

Lumos Diagnostics (ASX: LDX) has today announced it has signed an agreement...

Subscribe for Lumos news

By entering your email address you are agreeing to our Privacy Policy.

Innovation at the point-of-care

2024 Lumos Diagnostics

Quick links
Engage with us